4 – 5 November 2019 Bethesda, MD: The third annual Geroscience Summit was organized by the Trans-NIH Geroscience Interest Group (GSIG). The Geroscience Summit is hosted by the National Institute of Health, and brings together interdisciplinary experts in the field of age-related diseases to bring their expertise to the field of geroscience. Geroscience seeks interdisciplinary […]
13 – 17 October 2019 Denver, CO: The American Association for Laboratory Animal Science‘s (AALAS) National Meeting is the largest meeting in the world dedicated to the care, production, and use of laboratory animals. This year Ichor was represented by Dr. Danique Wortel, DVM, attending veterinarian, and Dr. Forrest Wright, PhD, Operations Manager of Husbandry. […]
23 October 2019 London, England: This year, the Global Innovation and New Technology (GIANT) Health Event took place on October 15 – 16 in London. This event brought thousands of pioneers among the health tech industry. Among them was Dr. Kelsey Moody, CEO at Ichor Therapeutics. Lysoclear develops a therapy to treat age-related macular degeneration […]
12 July 2019 NEW YORK, NY: The second annual Life Extension Advocacy Foundation (LEAF) Ending Age Related Diseases Conference was held in New York City July 11-12th. This conference brought together many of the top minds in the biotechnology rejuvenation field, including Dr. Kelsey Moody, CEO at Ichor Therapeutics, Inc. Dr. Moody also held a workshop prior to the conference, on July 10th. The workshop was held in the Cooper Union […]
On May 21st, 2019 ten Ichor employees participated in the JP Morgan Corporate Challenge at Onondaga Lake Park. The Ichor team ran 3.5 miles (5.6km) alongside many other local companies in order to raise money for the non-profit organization, Syracuse Stage, while encouraging health and fitness in the workplace, camaraderie amongst employees, and promoting an overall environmentally friendly lifestyle. At this event, Jacob McAndrew, Operations Manager of Cell Biology at Ichor Therapeutics, Inc., placed 6th out of 5,000 participants, with a time of 19:01.
Auctus Biologcs, Inc., a new portfolio company of Ichor Therapeutics, Inc., announced today the closure of $1.5MM in seed funding. The company will develop RPtag, a hyper-stable antibody mimetic scaffold published earlier this year in the peer-reviewed journal ACS Biochemistry, to take on conventional clinical antibody therapy as an orally bioavailable formulation. New high priority immunosenescence and gastrointestinal targets will also be pursued.
The State University of New York College of Environmental Science and Forestry (ESF) and Ichor Therapeutics are partnering to train graduate students in researching drugs that could combat age-related illnesses.
Ichor Therapeutics, a biotechnology company that develops therapeutic interventions for age-associated disease, announced the formation of Grapeseed.Bio, a life science strategic fund and accelerator program.
A small biotech company in Central New York is getting a big shot in the arm from some British investors.
Antoxerene, Inc., a portfolio company of Ichor Therapeutics, Inc., focused on small molecule drug discovery for pathways of aging, announced today the launch of a joint venture with Juvenescence Limited. The joint venture, called FoxBio, Inc., will develop Antoxerene’s collection of small molecules that target senescent cells. Juvenescence will support the venture with $10 million in equity financing and drug development expertise.